HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Rigel Pharmaceuticals, maintaining a price target of $57. This suggests confidence in Rigel's future performance.
September 05, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Rigel Pharmaceuticals, maintaining a price target of $57. This indicates strong confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. suggests positive sentiment and confidence in Rigel Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100